Oncocyte Overview
Oncocyte (OCX) has a ROE of 231.74%, above the Technology sector average of 46.88%.
Get informed when a big investor buys or sells
+ Follow231.74%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for OCX is 231.74%. That is above the Technology sector average of 46.88%. Investors often review this figure alongside Oncocyte's historical trend and sector peers before judging valuation or financial health.
Against Technology companies, OCX currently prints 231.74% for ROE, while the sector average sits near 46.88%. That is roughly 394.4% above the sector mean. Large gaps often invite a closer look at Oncocyte's growth, margins, and balance sheet.
Return on Equity shows how effectively Oncocyte converts resources into returns. At 231.74%, OCX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting OCX's ROE (231.74%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Oncocyte's ROE against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.
